Volume 22 Issue 5
May  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(5): 764-767
LI Weipeng, LI Hui, HU Yongquan, TAO Xinquan, SHEN Yong, SUN Jingqiu, YUAN Chao. Preliminary study of SPECT-CT imaging with 99Tcm-MIBI nanoparticles in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy[J]. Chinese Journal of General Practice, 2024, 22(5): 764-767. doi: 10.16766/j.cnki.issn.1674-4152.003498
Citation: LI Weipeng, LI Hui, HU Yongquan, TAO Xinquan, SHEN Yong, SUN Jingqiu, YUAN Chao. Preliminary study of SPECT-CT imaging with 99Tcm-MIBI nanoparticles in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy[J]. Chinese Journal of General Practice, 2024, 22(5): 764-767. doi: 10.16766/j.cnki.issn.1674-4152.003498
shu

Preliminary study of SPECT-CT imaging with 99Tcm-MIBI nanoparticles in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy

doi: 10.16766/j.cnki.issn.1674-4152.003498

  • Department of Nuclear Medicine, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2023AH052016

 2020byzd097

  • Received Date: 2024-01-11
    Abstract
  •   Objective  To explore the value of SPECT-CT imaging with 99Tcm-MIBI nanoparticle in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy, to find a non-invasive evaluation method to predict the efficacy of neoadjuvant chemotherapy.  Methods  The imaging agent 99Tcm-MIBI nanoparticle was prepared and the nude mouse model of carcinoma of breast was established. The nude mouse model was treated with combination chemotherapy of epirubicin and docetaxel (ET) as follows: on the 1st day, epirubicin 40 mg/(m·d) was administered via tail vein for two days, then on the 3rd day, docetaxel 60 mg/m2 was administered via tail vein, 3 weeks per cycle, with a total of 3 cycles of chemotherapy. 99Tcm-MIBI nanoparticles SPECT-CT imaging was used before and after chemotherapy to observe the image changes. The ratio of tumor to surrounding background (T/B) of each nude mouse model of breast cancer was calculated by ROI technology.  Results  According to UICC solid tumor efficacy evaluation criteria, the efficacy of combined chemotherapy in nude mice with human breast cancer was evaluated, In 40 nude mouse models of human breast cancer, 27 partial remission (PR), 12 disease stability (SD), and 1 disease progression (PD); The T/B of 99Tcm-MIBI nanoparticles SPECT-CT imaging before chemotherapy in nude mouse model of human breast cancer was 2.98±0.73, The T/B value of 99Tcm-MIBI nanoparticle SPECT-CT imaging after chemotherapy in the partially relieved (PR) nude mouse model was 1.52±0.59, and there was a significant difference in T/B value compared to before chemotherapy (P<0.05); The T/B of 99Tcm-MIBI nanoparticle SPECT-CT imaging in the disease stable (SD) nude mouse model after chemotherapy was 3.12±1.09, and the difference was not significant compared to before chemotherapy (P>0.05).  Conclusion  For breast cancer patients, 99Tcm-MIBI nanoparticles SPECT-CT imaging is expected to evaluate the therapeutic effect of neoadjuvant chemotherapy drugs, which is a non-invasive method to evaluate the drug resistance of breast cancer to neoadjuvant chemotherapy.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    TERUYA N, INOUE H, HORⅡ R, et al. Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer[J]. Cancer Med, 2023, 12(9): 10526-10535. doi: 10.1002/cam4.5788
    [2]
    AKAMINE Y, YASUI-FURUKORI N, UNO T. Drug-drug interactions of P-gp substrates unrelated to CYP metabolism[J]. Curr Drug Metab, 2019, 20(2): 124-129. doi: 10.2174/1389200219666181003142036
    [3]
    WEI X, SONG M, LI W, et al. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance[J]. Theranostics, 2021, 11(13): 6334-6354. doi: 10.7150/thno.59342
    [4]
    GOMES C M, ABRUNHOSA A J, PAUWELS E K, et al. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99Tcm] sestamibi and [99Tcm] tetrofosmin[J]. Cancer Biother Radiopharm, 2009, 24(2): 215-217.
    [5]
    BURAK Z, MORETTI J L, ERSOY O, et al. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression[J]. J Nucl Med, 2003, 44(9): 1394-1401.
    [6]
    DUAN X Y, WANG J S, LIU M, et al. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer[J]. Ann Nucl Med, 2008, 22(1): 49-55. doi: 10.1007/s12149-007-0080-5
    [7]
    袁超, 张勇, 焦举, 等. 载雄激素受体三螺旋形成寡核苷酸PEG-PLGA纳米粒子的制备与应用[J]. 中山大学学报(医学科学版), 2008, 29(5): 602-605. doi: 10.3321/j.issn:1672-3554.2008.05.022

    YUAN C, ZHANG Y, JIAO J, et al. Preparation and application of PEG-PLGA nanoparticles loaded with androgen receptor triple helix forming oligonucleotides[J]. Journal of Sun Yat Sen University (Medical Science Edition), 2008, 29(5): 602-605. doi: 10.3321/j.issn:1672-3554.2008.05.022
    [8]
    BELHAJ-TAYEB H, BRIANE D, VERGOTE J, et al. In vitro and in vivo study of 99mTc-MIBI encapsulated in PEG-liposomes: a promising radiotracer for tumour imaging[J]. Eur J Nucl Med Mol Imaging, 2003, 30(4): 502-509. doi: 10.1007/s00259-002-1038-4
    [9]
    袁超, 李辉, 申勇, 等. 99Tcm-MIBI脂质体纳米粒制备及生物分布实验研究[J]. 中华全科医学, 2018, 16(50): 721-724. doi: 10.16766/j.cnki.issn.1674-4152.000196

    YUAN C, LI H, SHEN Y, et al. Preparation of 99Tcm-MIBI liposome nanoparticles and experimental study on their biological distribution[J]. Chinese Journal of General Practice, 2018, 16(50): 721-724. doi: 10.16766/j.cnki.issn.1674-4152.000196
    [10]
    LOPES-RODRIGUES V, DI LUAC A, SOUSA D, et al. Data supporting the shedding of larger extracellular vesicles by multidrug resistant tumour cells[J]. Data Brief, 2016, 6(3): 1023-1027.
    [11]
    MA J, ZHAO Z, WU K, et al. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC[J]. Gene, 2016, 587(2): 147-154. doi: 10.1016/j.gene.2016.04.054
    [12]
    ALEXIOU G A, XOURGIA X, VARTHOLOMATOS E, et al. Comparison of 99mTc-tetrofosmin and 99mTc-sestamibi uptake in glioma cell lines: the role of p-glycoprotein expression[J]. Int J Mol Imaging, 2014, 2014: 471032. DOI. org/10.1155/2014/471032.
    [13]
    YANG T J, AUKEMA T S, VAN TINTEREN H, et al. Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer[J]. Mol Imaging Biol, 2010, 12(2): 174-180. doi: 10.1007/s11307-009-0250-z
    [14]
    陆智祥, 江勇, 余大富, 等. 非霍奇金淋巴瘤化疗后99Tcm-MIBI显像的价值[J]. 实用医学杂志, 2015, 31(22): 3732-3735. doi: 10.3969/j.issn.1006-5725.2015.22.032

    LU Z X, JIANG Y, YU D F, et al. The value of 99Tcm-MIBI imaging in non Hodgkin ' s lymphoma after chemotherapy[J]. Journal of Practical Medicine, 2015, 31(22): 3732-3735. doi: 10.3969/j.issn.1006-5725.2015.22.032
    [15]
    江生, 黄志顺, 肖国有. 99Tcm-MIBI乳腺亲肿瘤显像对乳腺癌的诊断价值分析[J]. 中国医学装备, 2021, 18(1): 63-67. doi: 10.3969/J.ISSN.1672-8270.2021.01.016

    JIANG S, HUANG Z S, XIAO G Y. Analysis of the diagnostic value of 99Tcm-MIBI breast tumor imaging for breast cancer[J]. Chinese Medical Equipment, 2021, 18(1): 63-67. doi: 10.3969/J.ISSN.1672-8270.2021.01.016
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (59) PDF downloads(4) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return